Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02129647 · ClinicalTrials.gov registry record · Phase 2
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT02129647 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 13 participants.
The verdict
NCT02129647, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the study drug, AXITINIB, has any effect on tumors found in patients with Neurofibromatosis Type 2 (NF2).
Interventions
- DRUG Axitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2014-04 |
| Est. Completion | 2019-02-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02129647
The ClinicalTrials.gov registry entry for NCT02129647 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Axitinib is the first listed.
NCT02129647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02129647 about?
NCT02129647 is a clinical study titled "Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas". The purpose of this study is to determine if the study drug, AXITINIB, has any effect on tumors found in patients with Neurofibromatosis Type 2 (NF2).
What is the current status of trial NCT02129647?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2014-04. Estimated completion is 2019-02-05.
What interventions are being tested in trial NCT02129647?
The interventions under investigation include: Axitinib (DRUG).
Who is sponsoring clinical trial NCT02129647?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.